Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Necrotizing autoimmune myopathy (NAM) is a rare form of idiopathic inflammatory myopathy characterized clinically by acute or subacute proximal muscle weakness, and histopathologically by myocyte necrosis and regeneration without significant inflammation.
Biomarker and diagnostic research for immune-mediated necrotizing myopathy has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
11 clinical trials registered, 4 recruiting. Interventions under study include biologic therapy, drug therapy, and other interventions. Pipeline includes 1 PHASE3, 6 PHASE2, 3 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06249438](https://clinicaltrials.gov/study/NCT06249438) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 3:03 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy |
PHASE1 |
RenJi Hospital |
RECRUITING |
[NCT06371417](https://clinicaltrials.gov/study/NCT06371417) | Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | PHASE1 | Chugai Pharmaceutical | RECRUITING |
[NCT07374107](https://clinicaltrials.gov/study/NCT07374107) | MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) | — | Myositis International Health & Research Collaborative Alliance Foundation | RECRUITING |
[NCT06154252](https://clinicaltrials.gov/study/NCT06154252) | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | PHASE2 | Cabaletta Bio | RECRUITING |
192 publications have been identified in PubMed for immune-mediated necrotizing myopathy. Research spans Case Report / Case Series (34%), Basic Science / Preclinical (20%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 65 | 34% |
Laboratory research | 38 | 20% |
Research summaries | 27 | 14% |
Disease patterns and progression | 26 | 14% |
Testing and diagnosis research | 16 | 8% |
Clinical study results | 11 | 6% |
Other research | 7 | 4% |
New treatment approaches | 2 | 1% |
Pei B (2026). [PMID: 41946117](https://pubmed.ncbi.nlm.nih.gov/41946117/). *Med Clin (Barc)*. [Epidemiology / Natural History]
Lueck BD (2026). [PMID: 41834235](https://pubmed.ncbi.nlm.nih.gov/41834235/). *Am J Case Rep*. [Case Report / Case Series]
Oğuz E (2026). [PMID: 41065672](https://pubmed.ncbi.nlm.nih.gov/41065672/). *Mod Rheumatol*. [Epidemiology / Natural History]
Lynn SD (2026). [PMID: 41988628](https://pubmed.ncbi.nlm.nih.gov/41988628/). *Cureus*. [Case Report / Case Series]
Dinh TN (2026). [PMID: 41270801](https://pubmed.ncbi.nlm.nih.gov/41270801/). *Rheumatology (Oxford, England)*. [Basic Science / Preclinical]
Gao M (2026). [PMID: 41622430](https://pubmed.ncbi.nlm.nih.gov/41622430/). *Neuropathology : official journal of the Japanese Society of Neuropathology*. [Diagnostic / Biomarker]
Mali M (2026). [PMID: 42053859](https://pubmed.ncbi.nlm.nih.gov/42053859/). *Clin Rheumatol*. [Case Report / Case Series]
Ong JT (2026). [PMID: 42037837](https://pubmed.ncbi.nlm.nih.gov/42037837/). *Cureus*. [Case Report / Case Series]
Mossakowski AA (2026). [PMID: 41650628](https://pubmed.ncbi.nlm.nih.gov/41650628/). *Neuromuscul Disord*. [Case Report / Case Series]
Annous L (2026). [PMID: 41783877](https://pubmed.ncbi.nlm.nih.gov/41783877/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning immune-mediated necrotizing myopathy
Updated Aug 6, 2026
A cohort study involving 23 patients has been conducted to investigate seropositive immune-mediated necrotizing myopathy. The findings may provide insights into the disease's characteristics and potential treatment approaches.
Two case reports highlight a rare association between anti-SRP antibody-positive immune-mediated necrotizing myopathy and Sjögren's disease. This discovery may provide insights into the overlapping mechanisms of these conditions.
A recent study highlights spontaneous remission in patients with statin-associated HMGCR-positive immune-mediated necrotizing myopathy following statin withdrawal. This finding could influence treatment strategies for this rare condition.
The MIHRA initiative focuses on gathering patient-rooted insights to shape research in myositis and related conditions. Sponsored by multiple organizations, including Myositis International and The Myositis Association, this project emphasizes qualitative investigations to better understand patient experiences.